Article
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.
Leukemia - 1 Sept 2026
Beird Hannah C, Kannan Sankaranarayanan, Liu Jingjing, Chen Janice, Olguin Arturo, Desai Poonam, Cai Tianyu, Han Lina, Cotton Jennifer L, Singh Sandeep, Gupta Saurabh Kumar, Little Latasha, Estecio Marcos R, Song Xingzhi, Abbas Hussein A, Zhang Jianhua, Gumbs Curtis, Brooks Christopher, Kantarjian Hagop, Andreeff Michael, Konopleva Marina, Futreal P Andrew, Pemmaraju Naveen
Abstract excerpt
Tagraxofusp is a CD123-targeted therapy comprised of a recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin payload. It is the first approved treatment specifically for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To identify biomarkers of response, bone marrow samples from 12 BPDCN patients who were treated with tagraxofusp in the pivotal phase II trial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.